Treating microvascular dysfunction
AssigneeEndoProtech, Inc.
InventorsClaudio Maldonado, Phillip Bauer
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions comprising phospho-lipids, lipid vesicles, and/or liposomes, and methods of use thereof. In one aspect, the present disclosure relates to methods and compositions for delivery of, biologically active lipids to reduce microvascular dysfunction and infarct size during revascularization of the blocked artery in a mammalian subject.
Claims8
A method for treating microvascular dysfunction, the method consisting of administering, to a subject in need thereof, an effective amount of nanoliposomes consisting of one or more negatively charged phospholipids, one or more neutrally charged phospholipids, a polyunsaturated fatty acid (PUFA) and a lysosphingolipid,
- wherein the neutrally charged phospholipids are selected from the group consisting of phosphatidylcholine (PC) and phosphatidylethanolamine (PE), or a combination thereof, and the negatively charged phospholipids are selected from the group consisting of phosphatidic acid (PA), phosphatidylserine (PS), and phosphatidylgylcerol (PG), or a combination thereof, wherein within 15 minutes of exposure to endothelial cells, at least 5% nanoliposomes are bound or fused to the endothelial cells,
- wherein the PUFA in the nanoliposomes constitutes 1%-5% of the nanoliposomes by weight and the lysosphingolipid in the nanoliposomes constitutes 0.1%-0.5% of the nanoliposomes by weight.
A method for inhibiting endothelial cell or immune cell activation, the method consisting of
- administering a therapeutic effective amount of a composition consisting of one or more negatively charged phospholipids, one or more neutrally charged phospholipids, a polyunsaturated fatty acid (PUFA) and a lysosphingolipid, to a subject in need thereof, wherein the composition is administered via intra-arterial delivery, wherein the PUFA in the nanoliposomes constitutes 1%-5% of the nanoliposomes by weight and the lysosphingolipid in the nanoliposomes constitutes 0.1%-0.5% of the nanoliposomes by weight.
A method for inhibiting endothelial cell activation, the method consisting of administering to a subject in need thereof a plurality of nanoliposomes consisting of one or more negatively charged phospholipids, one or more neutrally charged phospholipids, a polyunsaturated fatty acid (PUFA) and a lysosphingolipid,
- wherein the neutrally charged phospholipids are selected from the group consisting of phosphatidylcholine (PC) and phosphatidylethanolamine (PE), or a combination thereof, and the negatively charged phospholipids are selected from the group consisting of phosphatidic acid (PA), phosphatidylserine (PS), and phosphatidylgylcerol (PG), or a combination thereof,
- wherein within 15 minutes of exposure to endothelial cells, at least 5% nanoliposomes are bound or fused to the endothelial cells, wherein the PUFA in the nanoliposomes constitutes 1%-5% of the nanoliposomes by weight and the lysosphingolipid in the nanoliposomes constitutes 0.1%-0.5% of the nanoliposomes by weight.
Dependencies are inferred from the claim text.